Cortisol Deficiency: Frequent, Life-Impairing, and How to Give Patients Their Lives Back by Correcting It, Part 2

Thierry Hertoghe, MD

Part 1 that discusses the signs and symptoms of cortisol deficiency appears in the January 2018 issue and is also available online.

To Treat or Not to Treat Cortisol Deficiency?

People with cortisol deficiency who do not get treatment continue suffering from the psychic and physical consequences of cortisol deficiency at every moment of their lives. In the long term, the absence of treatment permits the cortisol deficiency to aggravate and produce chronic inflammatory diseases such as rheumatoid arthritis and psychological disorders, from irritability to the extreme form of paranoid psychosis. Because of the adverse consequences of not treating cortisol deficiency, forgoing treatment is not really an option.

Natural Treatments to Improve Cortisol Levels

The first natural treatment to get a higher cortisol level is to increase light.¹⁵⁴ After moving from a dark room into full daylight, an individual’s cortisol level increases by 50% or more within minutes. Thus, the golden rule is to expose oneself to more light: switching all the lights on in the office and at home and going outdoors at least once a day in full daylight for a minimum of half an hour. This quickly increases not only cortisol levels but also the number of cortisol receptors.

Second, it is of great importance to breathe cleaner air and eat organic foods to avoid airborne and foodborne pollutants, as toxins usually aggress the zona fasciculata of the adrenal glands that produces cortisol or block the target cells’ glucocorticoid receptors, inhibiting part of the action of cortisol.

One of these irritant pollutants is formaldehyde,¹⁵⁵ which pollutes many homes and offices. It is part of many types of glue that fix floor coverings to the ground and bind compressed wood together in home and office furniture. It is often part of plastic carpets and toys and slowly outgasses from these objects into the indoor atmosphere over the years, being inhaled through breathing. What to do about it? Apart from getting rid of these formaldehyde-containing materials inside homes, simply open the windows in rooms where such materials are and let outdoor air enter. Regularly ventilating rooms with outdoor air drastically reduces the formaldehyde concentration in the indoor air and, thus, the risk of adrenal gland damage.

Third, increasing the consumption of protein-rich foods,^156-157 such as meat, poultry, and fish, and fat-rich foods,^158-161 such as eggs, yolk, butter (preferably clarified butter), liver, and other organ meats, elevates the cortisol production and level by providing the ingredients for production of cortisol. Augmenting protein is not always easy with patients with cortisol deficiency, as they tend to accumulate nitrogen in the blood by consuming these nitrogen-rich foods. Indeed, once they consume meat and other protein-rich foods, the high level of nitrogen in their blood (azotemia) gives them nausea and disgust for meat. Fat intake also poses problems, as fats seem hard to digest by these patients, frequently causing indigestion. The solution consists of correcting the cortisol deficiency with a cortisol supplement and encouraging the patients to increase the intake of the protein- and fat-rich foods they tolerate.

People with cortisol deficiency should also avoid “bad” carbs, carbohydrate-rich foods that reduce the production of cortisol, like sweets, sugars,¹⁶² unsprouted bread, muesli, porridge, and rice. These foods can reduce the secretion of cortisol by 20–40%, enough to create problems. If ever they give in to the temptation of a chocolate bar or soft drinks, let them do it after a healthy meal, which dilutes the sugar into a bigger volume, reducing sugar’s hyperglycemic effect that blocks cortisol production (peak levels of glucose inhibit cortisol release).

Fourth, some rare nutritional supplements can help the adrenal glands function better, although modestly. Vitamin C is one of them.^163-164 With 500 mg to 2 g of vitamin C a day, the action of cortisol may get a boost. L-acetyl-carnitine, the activated form of L-carnitine, is another nutrient whose intake has been shown to significantly increase serum cortisol levels in humans.¹⁶⁵ A dose of 2 g/day may be efficient.

Fifth, several herbal extracts may weakly mimic cortisol activity by increasing its bioavailability and stimulating cortisol receptors, providing limited relief to adrenal-deficient patients. Plants also produce hormones that may have beneficial effects in humans. Extracts of licorice root may, for example, lessen complaints in patients with cortisol deficiency.^166-167 In my experience, licorice root extract has about 10-25% of the beneficial action of an adequate cortisol or hydrocortisone treatment.

Sixth, as the storage of cortisol in the adrenal glands is small in patients with adrenal deficiency, these patients should avoid exposing themselves to any unnecessary stressors, which deplete the adrenals of their cortisol stores. Selecting jobs and leisure activities that do not put excessive strain on the adrenal glands may be a wise decision for people who do not get or want to take a cortisol treatment. Spiritual meditation has been reported to be helpful in improving cortisol levels. Regular meditators respond to stressful conditions with a greater production of cortisol than non-meditators, while the cortisol level is lower in resting states, minimizing spillage.¹⁶⁸

Table 1 summarizes the main interventions you can do yourself with the help of a nutritionist to improve your cortisol secretion.

Glucocorticoid Treatment of Cortisol Deficiency

Glucocorticoid is the common name given to the whole family of natural or synthetically produced cortisol-like molecules, which share the property of increasing the blood sugar levels. “Gluco” means “glucose” (sugar), and “corticoid” signifies that it “comes from the cortex,” the outer part of the adrenal glands that produces this type of hormone. The human body makes two major bioidentical glucocorticoids: cortisol and cortisone. Bioidentical means that these hormones have the same molecular structure as the body’s own corresponding compounds. Corticosterone, which in rodents is more potent than cortisol, is another natural hormone that is found in humans.

Cortisol, also called hydrocortisone when it is used in therapy, is the body’s most potent glucocorticoid hormone. Cortisone is the precursor glucocorticoid made by the adrenals. It has 80% of cortisol’s action. Supplementation with cortisone is therefore always at a slightly higher dosage than with cortisol or hydrocortisone to get the same effects: To do the same job, 25 mg per day of cortisone is needed where the body requires 20 mg of hydrocortisone.

However, the name cortisone is misleadingly used nowadays to name synthetic derivatives of cortisol, such as prednisone and methylprednisolone. These compounds are not identical to the body’s own cortisol and cortisone. They may have different effects and indications. They are also used at lower dosages, as they have more potent effects.

Bioidentical glucocorticoids have better psychological effects and improve the blood pressure better than synthetic derivatives. The use of bioidentical cortisol and cortisone is indicated to treat most cases of cortisol deficiency, particularly when the predominant complaints are psychological. Bioidentical glucocorticoids better improve the mind, mood, energy, stress resistance, and other personality features compared to non-bioidentical glucocorticoids^169-172 because they are entirely adapted to the human body, particularly its glucocorticoid receptors.

Hydrocortisone is also a better choice to treat arterial hypotension because it retains salt and water more than synthetic derivatives.

Safety of Bioidentical Hormones

Because cortisol and cortisone are completely adapted to the human body, they are also safer. The risk of side effects such as skin atrophy is lower with these bioidentical glucocorticoids than with synthetic derivatives.¹⁷³ Long-term behavioral outcome and neuromotor development are also better in children who neonatally have received hydrocortisone rather than synthetic dexamethasone to avoid bronchial dysplasia.¹⁷² Whenever side effects, usually overdose symptoms, occur with these natural compounds, they persist for a shorter time (6-24 hours) because of a quicker breakdown and inactivation by the body than when caused by synthetic derivatives (a few days). For this reason, at comparable doses, cortisol and cortisone reduce the endogenous cortisol production of the adrenal glands considerably less than synthetic derivatives. The risk of adrenal gland suppression is also less with bioidentical glucocorticoids.^51,174-175

Table 2 (adapted from Chrousos et al., 2011)⁵¹ shows that synthetic derivatives of cortisol at equivalent doses suppress the adrenal glands more. The greater their glucocorticoid (and thus anti-inflammatory) potency, the more they suppress the endogenous cortisol secretion.

Table 2. Comparison of Synthetic Cortisol Derivatives

The safety of all these glucocorticoids is greatly increased with the use of lower doses of glucocorticoids, such as 30 mg/day or less of hydrocortisone and 5 mg/day or less of prednisolone.²⁸

Non-bioidentical glucocorticoids reduce inflammation better but may suppress the adrenal glands more. Non-bioidentical glucocorticoids, such as prednisone, prednisolone, methylprednisolone, and dexamethasone, are more indicated than bioidentical cortisol whenever inflammation prevails. Indeed, these compounds reduce inflammation more efficiently and persistently due to their (much) longer duration of action, usually 24 hours or more after intake (see table above).^{51,56,176-178} A good strategy is to prescribe them for a limited time (2–6 months is the time necessary to reduce the inflammation) and then switch to bioidentical cortisol once the inflammation is gone.

As previously mentioned, there are two bioidentical hormones available at pharmacies: cortisol (usually delivered under its synonym, hydrocortisone) and cortisone (the precursor to cortisol, with 20% less potency). In most cases, for patients with no tendency toward high blood pressure, being overweight, or swelling of the feet, hydrocortisone is the preferred treatment.¹⁷⁹ The science behind bioidentical cortisol treatment is strong. Pubmed, the main Internet medical databank, presents 270 placebo-controlled studies in adults (almost all double-blind; 256 with systemic therapies,^180-433 14 with topical therapies^434-447).

Daily Cortisol Production

How much cortisol do humans produce? Researchers have found that the cortisol production rate in sedentary adults assessed in an in-hospital resting unit is on average more in men (22.5 mg per 24 hours) than in women (9.2 mg per 24 hours)⁴⁴⁸ due to the bigger body surface area and adrenal glands of men. The average body surface area is 1.9 m² in men and 1.6 m² in women.⁴⁴⁹ Other investigators have found lower cortisol levels in men, an average of 9.1-10.9 mg/m² of the body,^450-451 which equals about 17.3- 20.7 mg/day of cortisol for men with average body surface area.

However, these productions are valid only for sedentary resting conditions in laboratory units. In real life, the multiple mental and physical activities and higher stress conditions require and stimulate the adrenal glands to produce more cortisol. An average day in “real life” conditions requires at least 30–50% more cortisol production so that the real daily average cortisol production is probably 30 mg/day in men and 20 mg/day in women.

In people with heavy physical activity, daily cortisol production may even triple. Urinary cortisol excretion in female long-distance runners, for example, is threefold higher than that in sedentary persons.⁴⁵²

How much cortisol do cortisol-deficient patients need? My personal experience is that doses of less than 15 mg/day in female and less than 20 mg/day in male cortisol-deficient adults, respectively, do not work well. At too-low doses, patients feel—after an initial modest and short improvement in cortisol activity two-to-four hours after intake—a noticeable drop in energy, due to a fall in cortisol activity. Low doses of 5–10 mg/day of cortisol are just not sufficient to keep the baseline cortisol levels high enough for a satisfying quality of life.

How much cortisol is absorbed after intestinal intake? Does this mean that we need a maximum of 20 to 30 mg per day cortisol intake to correct a near total deficiency? No, because, on average, less than half – only 43% – of oral hydrocortisone (cortisol) is absorbed.⁴⁵³ This means that a patient who does not have any cortisol production, needs to take a dose equivalent to double the normal endogenous cortisol production – 40 to 60 mg per day of oral hydrocortisone – to compensate for the absence of endogenous cortisol production.

In fact, cortisol absorption in the intestines might even be lower because the 43% of hydrocortisone absorption was measured in optimal conditions in which hydrocortisone was perfused with water in the intestinal lumen. The more water is added, the more hydrocortisone is absorbed. Thus, water intake may improve hydrocortisone absorption.

Food ingestion before hydrocortisone intake, on the other hand, delays hydrocortisone absorption.⁴⁵⁴

Divided doses of hydrocortisone usually, but not always, work better. For most patients, hydrocortisone should be taken in divided doses, at least twice a day,^455-456 for example, a higher dose in the morning after waking and the remaining dose during lunch. I recommend taking doses 5-20 minutes before breakfast and lunch, but some people experience stomach irritation because of the acetate that is bound to the hydrocortisone; it is pharmaceutically delivered as hydrocortisone acetate, which is an acid, and not as hydrocortisone alone. To avoid acidity, the hydrocortisone can be taken after meals or, if problems persist, prescribe the hydrocortisone pills with a protective (enteric coated) layer for the stomach.

Some people need to divide the doses further into three to four smaller portions taken at regular intervals throughout the day.^454,456-458 In these cases, they can take a supplementary dose of 5 mg of hydrocortisone at 4 p.m. and before bedtime. The 5 mg of hydrocortisone at bedtime is too small to keep the patient awake at night, but it does provide better energy upon waking the next morning.

What if a patient forgets the second dose of hydrocortisone or cortisone at lunch? He or she should take it later (4 p.m., for example), but not too late (after evening meal). Patients who tend to forget to take the second dose can try taking the full daily dose after waking. Some people do fine and stay energized until bedtime; others do not and need two or even three bioidentical hydrocortisone or cortisone doses to feel well throughout the day.

Treatment with Synthetic Glucocorticoid Derivatives

In inflammatory diseases, such as the flu and rheumatoid arthritis, the synthetic cortisol derivative prednisone and its active metabolite, prednisolone, provide more efficient relief and the ability to avoid permanent adverse consequences, such as joint deformations, thanks to their prolonged duration of action.^51,459-460

In overweight people and individuals with a tendency to foot edema and arterial hypertension, permanent use of methylprednisolone is generally a better option because, at equivalent doses, it retains less water and weight and increases blood pressure less than other glucocorticoids, particularly much less than the bioidentical hydrocortisone. When I prescribe it, I start with a period of two to six months and may continue administering it if the patient remains prone to the aforementioned disorders.

Table 3 (adapted from Chrousos et al., 2011)⁵¹ below shows the absence at physiological dose of the water-retaining and blood pressure-increasing effect of methylprednisolone compared to cortisol and prednisone.

Table 3. Glucocorticoid Hypertensive Potencies

Dexamethasone is a potent synthetic derivative of cortisol. A dose of 0.25 mg of dexamethasone equals the activity of 20 mg of hydrocortisone. Because of its longer 48-hour duration of action, dexamethasone may considerably reduce adrenal hormone secretion, including the production of androgens (male hormones). Dexamethasone’s capacity to drastically reduce adrenal androgens is useful in reducing excessive body hair growth in women resulting from an excessive production of adrenal androgens. A once-daily morning intake of dexamethasone is usually sufficient to considerably suppress adrenal androgen production for more than 24 hours. I do not find its intake every two days efficient, as patients do not usually feel well on the second day, perhaps due to recurrence of adrenal deficiency.

To reduce skin rashes or to avoid keloid (voluminous scar) formation, a cream of 1-3% hydrocortisone may prove efficient. A concentration of 3% equals 30 mg of hydrocortisone per gram of cream. If this does not suffice, a lotion with a synthetic glucocorticoid derivative may help, but only if the area of skin application is small (several square centimeters), otherwise too much of the more potent synthetic derivative will penetrate through the skin into the body and cause side effects.

In emergencies, injections with high doses (50 to 250 mg) of cortisol or synthetic derivatives may be helpful, but this should be limited to exceptional cases as overdoses produce side effects. Table 4 summarizes the various cortisol treatments.

Table 4. Typical Glucocorticoid Treatment Schedules

Note: In most cases, the dose between parentheses is not administered, but there are exceptions in which intake is necessary for patients to benefit from continuous cortisol.

Dealing with Inflammation, Infections, Allergies, or Stresses

In nature, vigorous adrenal glands react to stress by increasing their secretion of cortisol and other adrenal hormones. People with adrenal deficiency have lost a great part of their ability to produce additional amounts of cortisol in cases of extra need. Their inability to increase their secretion of cortisol explains why they suffer from stress much more than people with healthy adrenal glands. Their excessive stress sensitivity can progress into a real hate of any kind of stress.

The solution for these patients is to mimic nature by taking additional cortisol in conditions where more cortisol is needed. Taking a dose of 5 mg of hydrocortisone, 1.25 mg of prednisolone or prednisone, or 1 mg of methylprednisolone every 30 minutes until mild or moderately important infections or stressful feelings disappear may do the job.^91,461 In cases of severe inflammation or infection, this small dosage may have to be doubled. In most cases, stressful feelings and infections disappear within two hours. Continuously increasing every 30 minutes for more than three hours is not recommended. The total amount of cortisol that may be needed the day of an infection or heavy stress may be the double or triple of the regular daily dose without any side effects other than the disappearance of inflammation or stress.

Transiently increasing cortisol is really efficient when the increase is applied

in the minutes that the patient feels the first signs of infection or stress

. The longer patients wait to increase their doses, the less efficient this method becomes. When I start to get a sore throat, or feel my body aching because of the flu, even if it is in the middle of the night, I take an extra dose of hydrocortisone or, even better, switch to 1 to 2.5 mg prednisolone or prednisone every 30 minutes. These synthetic glucocorticoids are more efficient in alleviating flu symptoms thanks to their greater anti-inflammatory effects and prolonged 24-hour action. In general, one, two, or three additional intakes every 30 minutes are necessary to alleviate flu symptoms or a sore throat.

When patients wait too long after the start of an infection – two days for example – to increase their cortisol treatment, they often do better by limiting the increase in cortisol intake to an average of 50% more than their usual daily dose and must often continue this higher dose for three to ten days to rid themselves of the persisting infection, inflammation, or allergy. Such a prolonged intake of a higher dose of cortisol is generally unnecessary when the patient intervenes quickly and increases the dose in the minutes after noticing the first signs of an infection or allergy symptoms.

In stressful conditions, such as speaking at a meeting or participating in a radio or TV show, people with adrenal deficiency greatly benefit from taking 5–10 mg, 30 minutes to two hours before speaking. They experience more punch and perform better.

Can people not on glucocorticoid treatment occasionally take cortisol? Each time a person has a flu or another type of viral infection or has to face a stressful event, occasional intake of cortisol (preferable with an equal amount of protective DHEA) may stimulate the immune system without harm so that the infection is overcome in a matter of hours if the patient reacts quickly. A dose of 5-10 mg of hydrocortisone before a stressful event or 20-30 mg in one intake at the occasion of an infection may be sufficient to alleviate acute viral infections.

Side Effects and Risks of Cortisol Treatment

Three types of side effects of cortisol treatment can occur:

• Overdose effects

  due to excessive cortisol levels.

• Imbalance effects

  due to an absence or deficiency in anabolic hormones, whose roles are to block any unwanted catabolic effects from cortisol.

• Adrenal gland suppression

  is when secretion of hormones by adrenal glands is partially or totally blocked by treatment through negative feedback to the pituitary gland’s secretion of ACTH.

Total suppression of the hormone secretions of the adrenal glands usually occurs only with very high glucocorticoid doses that are considerably higher than those proposed in Table 4. Total adrenal suppression may endanger life in cases in which cortisol secretion stops suddenly, as life is not sustainable without cortisol.

In general, at 20 to 30 mg per day of hydrocortisone, adrenal suppression is only partial (20–35%) and transient. After stopping these physiological doses, patients recover their initial cortisol secretion within two to six weeks. However, when very high doses are given for four to six months, as with some patients with severe rheumatoid disorders, the decrease in adrenal secretion of cortisol may persist for eight months before returning to the initial state.

Neglecting to correct other hormone deficits and a high-carb diet may increase the need for higher cortisol doses. In my experience, patients whose rheumatism does not sufficiently respond to physiological doses of cortisol, in fact, have other hormone deficiencies (testosterone, estrogen, thyroid, DHEA, etc.) that contribute to their rheumatoid disorder. Their diets (sweets, artificial sweeteners, grains) trigger inflammation and block cortisol action. These patients need to correct their diets and other hormone deficits, not to take pharmacological glucocorticoid doses.

How to Stop a Treatment

Patients on long-term high glucocorticoid doses should never abruptly stop their treatments. Rather, they should slowly decrease the dose over a period of two to four months, lowering their dose by 5 mg/day of cortisol or 1-1.25 mg/day of synthetic glucocorticoid every 10-14 days. If this slow and gradual decrease in cortisol supplementation does not gradually revive adrenal glands, regular stimulation of adrenal production with intramuscular injections of 1–2 mg of long-acting ACTH twice a week may restore cortisol production in two to four months.

Table 5 presents an overview of the most frequent complaints and physical signs of glucocorticoid treatment excess.

Additional Use of DHEA and Other Anabolic Hormones

Adrenal glands simultaneously secrete cortisol and protective hormones, such as DHEA and aldosterone. In young adults, secretion of both cortisol and its protective hormone DHEA by the adrenal glands are similar—approximately 20 mg per day for women and 30 mg per day for men. Whenever increased amounts of cortisol are secreted, healthy adrenal glands also release proportionately more DHEA and other adrenal hormones.

In many medical offices, cortisol or one of its derivatives are generally prescribed alone without protective anabolic hormones. This imbalanced treatment produces a number of side effects—mostly tissue atrophy—as shown in Table 5. To avoid these undesirable catabolic effects, DHEA and other anabolic hormones such as testosterone, female hormones, and possibly even growth hormone should be systematically administered (if the patient is deficient in these hormones), whenever hydrocortisone or one of its derivatives is prescribed.

Intolerance to Cortisol

A minority of cortisol-deficient patients, usually those with the weakest adrenals, does not tolerate oral intake of cortisol. They may experience unbearable stomach acidity that can be overcome by enrobing the cortisol in a protective coat (a supplementary layer at the outside of the pill). Enteric coating protects the stomach against the pills’ acidity by dissolving in the small intestine rather than in the stomach.

Patients may also feel weird, overwhelmed by a general malaise that spreads over the body with feelings of fainting and great weakness, when taking oral hydrocortisone or one of its synthetic derivatives. These patients find that cortisol therapy aggravates their cortisol deficiency symptoms. The usual cause is aldosterone deficiency induced or aggravated by glucocorticoid-induced reduction of pituitary secretion of ACTH, the hormone that stimulates secretion of all major hormones of the adrenal cortex. Aldosterone is another hormone secreted by the adrenal cortex. It keeps the blood pressure up. Treatment of aldosterone deficiency and its associated feeling of empty-headedness consists of adding fludrocortisone, the synthetic derivative of aldosterone.

A tiny minority of cortisol-deficient patients may still not tolerate or do well with cortisol, despite their desperate need for it. These cortisol-intolerant patients often experience all types of allergic or intolerance reactions to whatever medication they take. Their cortisol levels in blood and urine are usually dramatically low. Physicians may get headaches from trying to find strategies that could solve the problem.

Two alternate routes of administration may provide relief. Subcutaneous injections of cortisol at 30 to 50 mg a day may help, as may the application of 4–6 g/day of a liposomal gel with 5% cortisol applied to the buttocks, back, and belly in a very thin layer to avoid skin atrophy. A liposomal gel offers the best penetration of the body. If the applied layer is thin and if the patient rubs it ten times over a large surface, it should penetrate quickly, leaving the skin intact. I tried these two forms, and they provided the same efficacy as my daily 30 mg/day of hydrocortisone intake.

How to Make Cortisol Treatment Safe

First of all,

avoid excess

. Doses of 15–30 mg per day of hydrocortisone in women and 20–35 mg per day in men are usually physiologically safe^28-31 but may need to be reduced for smaller individuals. High cortisol doses should only be administered for a limited time in exceptional crises—to rescue a patient or an organ, for example—but always with concomitant anabolic hormone treatment.

The best method is to inform patients of cortisol excess signs and recommend they reduce the dose by 25 to 50% if there are ever signs of cortisol excess, such as a swollen face, weight gain, high blood pressure, or excessive agitation.

Second,

administer simultaneously protective anabolic hormones

. DHEA is the number one anabolic hormone that neutralizes excessive catabolic effects of cortisol associated with cortisol treatment.^35-39

Young adult adrenals secrete DHEA and other anabolic hormones concomitantly with cortisol. Because DHEA is anabolic and builds up tissue, its presence blocks the excessive catabolic effects of cortisol. Cortisol is predominantly catabolic because it hastens catabolism to eliminate excessive tissue and unblocks energy by breaking glycogen down into glucose.

Both catabolism and anabolism are essential for health, but they must be appropriately balanced. To do so, both cortisol and anabolic hormones, such as DHEA, should be given in equivalent doses. Physicians should therefore mimic nature and provide DHEA with cortisol to avoid tissue wasting.

With aging, the production of DHEA declines considerably more than that of cortisol, resulting in an imbalance that favors catabolism above anabolism, which explains the progressive acceleration of aging in individuals past the age of 45.

The third way to make cortisol treatment safe is to

avoid consuming “bad” carbohydrates

. In my experience, intake of sweet foods and cereals (that were not sprouted (such as traditional bread, pasta, muesli, porridge, etc.), tend to block the major beneficial effects of glucocorticoid treatment and to increase the occurrence and intensity of undesirable side effects, especially swelling and weight gain. Thus, patients should avoid bad carbs in their die

t

at least five days a week. A protein-rich diet (180 g/day or more of meat, fish, and poultry) is also protective against excess glucocorticoid catabolism.

Follow-Up

Follow-ups are mainly based on clinical assessments. More than for other hormone therapies, follow-ups of cortisol treatments should be done clinically for the most part, assessing for the presence of complaints and signs and avoiding any overdose signs.

Please note that saliva, serum, and 24-hour urine laboratory tests usually provide inconsistent results for follow-ups of bioidentical hydrocortisone and cortisone treatments. They are unstable and unreliable.

If hydrocortisone treatment is taken 30 minutes to three hours before blood and saliva tests, abnormally high free (and total) cortisol levels can be found in the serum due to peak levels of cortisol after absorption.

If hydrocortisone treatment at physiological doses is taken much later—seven to 24 hours after blood and saliva tests—cortisol levels usually drop back to their initial levels (from before treatment) or even to a supplementary 20-30% lower concentration (usually not more) because of transient and partial inhibition of the adrenal cortisol secretion.

In blood and saliva, cortisol levels are not stable during treatment. Not only is there a cortisol circadian rhythm, which makes cortisol levels fluctuate, with two to three times higher cortisol levels in the early morning than in late afternoon, but orally ingested cortisol does not bind strongly to cortisol-binding globulin (CBG), so the cortisol, which penetrates into the blood or saliva, quickly leaves for the target cells, decreasing cortisol levels.

The 24-hour urine test is not good for follow-ups either because it can show abnormally high levels of cortisol due to peak cortisol absorption with increased losses in urine, as well as unusually high excretion rates of cortisol metabolites (17-hydroxysteroids), even if cortisol treatment is adequate or insufficient. After intestinal absorption, the cortisol passes into the liver. Much of the cortisol is then broken down in the liver into inactive metabolites, which pass into the blood and then the urine, not reflecting real cortisol metabolic activity. The 24-hour urine is a must to control the reduction in adrenal androgens when dexamethasone is given to reduce body hair growth.

For non-bioidentical glucocorticoids, laboratory tests are even more inadequate for follow-up. None of the traditional laboratory tests can measure these synthetic glucocorticoids because of their different molecular structures. They might have some value to check the grade of adrenal suppression they may cause. Finding undetectable or nearly undetectable endogenous cortisol levels and very low metabolite levels in urine tests indicates that endogenous cortisol secretion by adrenal glands might be excessively suppressed by treatment, possibly by overdose.

Conclusion

Adrenal deficiency, particularly cortisol deficiency, is one of the most underestimated and misdiagnosed hormone deficiencies.

Untreated cortisol deficiency severely affects a patient’s quality of life and brings a long road of unnecessary suffering. The hormone cortisol makes most stress bearable and considerably reduces suffering. Patients who remain in cortisol deficiency suffer excessively and continue to do so throughout their lives – the more severe the deficiency, the more suffering there is.

Many physicians and laypeople are reluctant to prescribe or take supplements of cortisol or one of its derivatives because of the unacceptable side effects of pharmacological doses of cortisol. These fears should not prevent physicians from treating cortisol-deficient patients with small, well-adjusted physiological doses of cortisol that are balanced with a protective DHEA supplement.

To correct a cortisol deficiency, the first things to do are to improve the environment, the lifestyle, and the diet. Let patients expose themselves to daylight and intense indoor light more. Recommend that they avoid pollutants – most pollutants are indoors. Regularly meditating or relaxing may also help increase cortisol levels when supplementary amounts are necessary. Avoiding unnecessary stress preserves cortisol stores from spillage. In addition, increasing the intake of protein- and fat-rich foods and avoiding sweets and cereals may also noticeably improve cortisol levels. In a minority of cases, these interventions may suffice.

In all other cases where cortisol treatment must be installed, these interventions optimize treatment results.

References (References 1-153 in Part 1)

154. Leproult R, et al. Transition from dim to bright light in the morning induces an immediate elevation of cortisol levels. J Clin Endocrinol Metab. 2001 Jan;86(1):151-7.

155. Eberhagen D, Plette G, Hauck O. On the modification of lipid metabolism in the adrenal glands of the rat. 3. Studies after formaldehyde poisoning. Z Gesamte Exp Med. 1968;145(2):171-84.

156. Anderson KE, et al. Diet-hormone interactions: protein/carbohydrate ratio alters reciprocally the plasma levels of testosterone and cortisol and their respective binding globulins in man. Life Sci. 1987 May 4;40(18):1761-8.

157. Slag MF, et al. Meal stimulation of cortisol secretion: a protein induced effect. Metabolism. 1981 Nov;30(11):1104-8.

158. Civen M, et al. Effects of excess dietary cholesterol on adrenal cholesterol accumulation and steroidogenesis. J Steroid Biochem. 1984 Apr;20(4A):893-9. (Diets with 3% cholesterol … elevated adrenal corticosteroid levels (43%)).

159. Treviño Villarreal DC, et al. Relationship of serum cortisol and metabolic syndrome components, dietary intakes and anxiety disorder in children at 8 to 12 years of age with obesity. Nutr Hosp. 2012 Sep-Oct;27(5):1562-8.

160. Tannenbaum BM, et al. High-fat feeding alters both basal and stress-induced hypothalamic-pituitary-adrenal activity in the rat. Am J Physiol. 1997 Dec;273(6 Pt 1):E1168-77.

161. Takeuchi H, et al. Accelerative effect of olive oil on adrenal corticosterone secretion in rats loaded with single or repetitive immersion-restraint stress. J Nutr Sci Vitaminol (Tokyo). 2000 Aug;46(4):158-64.

162. Fernández-Real JM, Ricart W, Casamitjana R. Lower cortisol levels after oral glucose in subjects with insulin resistance and abdominal obesity. Clin Endocrinol (Oxf). 1997 Nov;47(5):583-8.

163. Kodama M, et al. Vitamin C infusion treatment enhances cortisol production of the adrenal via the pituitary ACTH route. In Vivo. 1994 Nov-Dec;8(6):1079-85.

164. Kodama M, et al. Intraperitoneal administration of ascorbic acid delays the turnover of 3H-labelled cortisol in the plasma of an ODS rat, but not in the Wistar rat. Evidence in support of the cardinal role of vitamin C in the progression of glucocorticoid synthesis. In Vivo. 1996 Jan-Feb;10(1):97-102.

165. Martignoni E, et al. Acetyl-L-carnitine acutely administered raises beta-endorphin and cortisol plasma levels in humans. Clin Neuropharmacol. 1988 Oct;11(5):472-7.

166. Methlie P, et al. Grapefruit juice and licorice increase cortisol availability in patients with Addison’s disease. Eur J Endocrinol. 2011 Nov;165(5):761-9. doi: 10.1530/EJE-11-0518.

167. Pratesi C, et al. Effects of licorice on urinary urinary metabolites of cortisol and cortisone. J Hypertens Suppl. 1991 Dec;9(6):S274-5

168. MacLean CR, et al. Effects of the Transcendental Meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. Psychoneuroendocrinology. 1997 May;22(4):277-95

169. Seifritz E, et al. Differential mood response to natural and synthetic corticosteroids after bilateral adrenalectomy: a case report. J Psychiatr Res. 1994 Jan-Feb;28(1):7-11. (A 48-year-old woman who had had a bilateral adrenalectomy for Cushing’s syndrome developed severe psychotic symptoms that were unresponsive to psychotropic drugs as long as she was taking prednisone (PRED) as replacement therapy. However, after she was switched to a regimen of cortisol (CORT) and fludrocortone (FLUD) the psychopathology disappeared. Mechanisms related to the differences in the interaction of natural (e.g. CORT) and synthetic (e.g. PRED) corticosteroids with the central glucocorticoid and mineralocorticoid receptors may explain the different effects upon psychopathology.)

170. Piguet B. Study of attacks of tetany and psychological disorders appearing during adrenal cortex hormone therapy: attacks of tetany and grave psychoses initiated by substitution of delta-cortisone for hydrocortisone and subsequently by ACTH. Rev Rhum Mal Osteoartic. 1958 Dec;25(12):814-28.

171. Benson S, et al. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. Eur J Endocrinol. 2012 Nov;167(5):679-85. (SAI patients showed improvements in physical quality of life (i.e. SF-36 physical function, P<0.05; physical role function, P<0.05) and current well-being (at 1800 h, P<0.05) under treatment A (hydrocortisone 10-0-5-0 mg) compared with the other replacement regimens)

172. van der Heide-Jalving M, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr. 2003 Jul;92(7):827-35 (DEX girls had a poorer performance on nearly all behavioral scales of the Teacher’s Report Form compared with HC girls. DEX boys did not differ from HC boys. The HC boys or girls did not differ from the REF or BMETH groups. Neuromotor development was poorer in DEX than the BMETH and REF groups.)

173. Hoffmann K, et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998 Mar;10(2):137-42.

174. Jacobs S, et al. Adrenal suppression following extradural steroids. Anaesthesia. 1983 Oct;38(10):953-6.

175. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999 May 10;159(9):941-55 (“Marked adrenal suppression occurs with high doses of inhaled corticosteroid above 1.5 mg/d (0.75 mg/d for fluticasone propionate), although there is a considerable degree of interindividual susceptibility”)

176. Endocrinology Volume 2:, 4^th edition, Ed. Degroot LL, Jameson JL, chapter 119: Adrenal Glands and glucocorticoids: p. 1672, table 119-1

177. Harter JC. Corticosteroids. NY State J Med. 1966;66:827-40

178. Longui CA, et al. Antiproliferative and apoptotic potencies of glucocorticoids: nonconcordance with their antiinflammatory and immunosuppressive properties. Arq Bras Endocrinol Metabol. 2005 Jun;49(3):378-83

179. Løvås K, Husebye ES. Replacement therapy for Addison’s disease: recent developments. Expert Opin Investig Drugs. 2008 Apr;17(4):497-509.

180. Roelfsema F, Aoun P, Veldhuis JD. Pulsatile Cortisol Feedback on ACTH Secretion Is Mediated by the Glucocorticoid Receptor and Modulated by Gender. J Clin Endocrinol Metab. 2016 Nov;101(11):4094-4102.

181. Kellner M, et al. No acute suppression of cerebrospinal fluid corticotropin-releasing hormone in man by cortisol administration. Psychiatry Res. 2013 Dec 15;210(2):662-4

182. Posener JA, et al. Cortisol feedback effects on plasma corticotropin levels in healthy subjects. Psychoneuroendocrinology. 1997 Apr;22(3):169-76.

183. Hamitouche N, et al. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. AAPS J. 2017 May;19(3):727-735.

184. Wilkinson CW, Peskind ER, Raskind MA. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology. 1997 Jan;65(1):79-90

185. Nass R, et al. Four-hour infusion of hydrocortisone does not suppress the nocturnal increase of circulating acyl- or desacyl-ghrelin concentrations in healthy young adults. J Clin Endocrinol Metab. 2014 Sep;99(9):E1696-700

186. Tops M, et al. Cortisol-induced increases of plasma oxytocin levels predict decreased immediate free recall of unpleasant words. Front Psychiatry. 2012 May 16;3:43.

187. Tops M, van Peer JM, Korf J. Individual differences in emotional expressivity predict oxytocin responses to cortisol administration: relevance to breast cancer? Biol Psychol. 2007 May;75(2):119-23

188. Porter RJ, et al. The effects of sub-chronic administration of hydrocortisone on hormonal and psychological responses to L-tryptophan in normal male volunteers. Psychopharmacology (Berl). 2002 Aug;163(1):68-75

189. Kasckow JW, et al. Circulating human corticotropin-releasing factor-binding protein levels following cortisol infusions. Life Sci. 2001 Jun 1;69(2):133-42.

190. Askari H, Liu J, Dagogo-Jack S. Hormonal regulation of human leptin in vivo: effects of hydrocortisone and insulin. Int J Obes Relat Metab Disord. 2000 Oct;24(10):1254-9.

191. Watson S, Porter RJ, Young AH. Effect of hydrocortisone on the pituitary response to growth hormone releasing hormone. Psychopharmacology (Berl). 2000 Sep;152(1):40-6.

192. Porter RJ, et al. 5-Hydroxytryptamine receptor function in humans is reduced by acute administration of hydrocortisone. Psychopharmacology (Berl). 1998 Oct;139(3):243-50.

193. Newcomer JW, et al. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Arch Gen Psychiatry. 1998 Nov;55(11):995-1000.

194. Young AH, Rue J, Odontiadis J, Cowen PJ. Lack of effect of hydrocortisone treatment on d-fenfluramine-mediated prolactin release. Psychopharmacology (Berl). 1998 Mar;136(2):198-200.

195. Dinan TG, Scott LV. The influence of cortisol on spontaneous and 5HT stimulated prolactin release in man. J Basic Clin Physiol Pharmacol. 1996;7(1):45-56

196. Friess E, et al. Effects of pulsatile cortisol infusion on sleep-EEG and nocturnal growth hormone release in healthy men. J Sleep Res. 1994 Jun;3(2):73-79

197. Lal S, et al. Effect of hydrocortisone on basal and apomorphine-induced growth hormone secretion in normal subjects. Clin Invest Med. 1988 Jun;11(3):218-23.

198. Clerc D, Wick H, Keller U. Acute cortisol excess results in unimpaired insulin action on lipolysis and branched chain amino acids, but not on glucose kinetics and C-peptide concentrations in man. Metabolism. 1986 May;35(5):404-10

199. Merz CJ, et al. Neural Underpinnings of Cortisol Effects on Fear Extinction. Neuropsychopharmacology. 2017 Sep 26. [Epub ahead of print]

200. Graebener AH, et al. Repeated cortisol administration does not reduce intrusive memories – A double blind placebo-controlled experimental study. Eur Neuropsychopharmacol. 2017 Sep 18. pii: S0924-977X(17)30903-3

201. Dinse HR, et al. The stress hormone cortisol blocks perceptual learning in humans. Psychoneuroendocrinology. 2017 Mar;77:63-67

202. Fleischer J, et al. The effect of cortisol on autobiographical memory retrieval depends on remoteness and valence of memories. Biol Psychol. 2017 Feb;123:136-140

203. Duesenberg M, et al. Effects of Hydrocortisone on false memory recognition in healthy men and women. Behav Neurosci. 2016 Dec;130(6):635-642.

204. Rombold F, et al. Impact of exogenous cortisol on the formation of intrusive memories in healthy women. J Psychiatr Res. 2016 Dec;83:71-78.

205. Kinner VL, et al. Cortisol disrupts the neural correlates of extinction recall. Neuroimage. 2016 Jun;133:233-43.

206. Margittai Z, Nave G, Strombach T, van Wingerden M, Schwabe L, Kalenscher T. Exogenous cortisol causes a shift from deliberative to intuitive thinking. Psychoneuroendocrinology. 2016 Feb;64:131-5.

207. Miller R, et al. Hydrocortisone accelerates the decay of iconic memory traces: on the modulation of executive and stimulus-driven constituents of sensory information maintenance. Psychoneuroendocrinology. 2015 Mar;53:148-58

208. Wiemers US, Wolf OT. Cortisol broadens memory of a non-stressful social interaction. Psychopharmacology (Berl). 2015 May;232(10):1727-33

209. Peifer C, et al. Cortisol effects on flow-experience. Psychopharmacology (Berl). 2015 Mar;232(6):1165-73.

210. Cioncoloni D, et al. Differential effects of acute cortisol administration on deep and shallow episodic memory traces: a study on healthy males. Neurobiol Learn Mem. 2014 Oct;114:186-92

211. Kandasamy N, et al. Cortisol shifts financial risk preferences. Proc Natl Acad Sci USA. 2014 Mar 4;111(9):3608-13.

212. Koessler S, et al. Stress eliminates retrieval-induced forgetting–does the oral application of cortisol? Psychoneuroendocrinology. 2013 Jan;38(1):94-106

213. Tops M, et al. Cortisol-induced increases of plasma oxytocin levels predict decreased immediate free recall of unpleasant words. Front Psychiatry. 2012 May 16;3:43.

214. Young K, et al. Dose-dependent effects of hydrocortisone infusion on autobiographical memory recall. Behav Neurosci. 2011 Oct;125(5):735-41

215. Wilhelm I, Wagner U, Born J. Opposite effects of cortisol on consolidation of temporal sequence memory during waking and sleep. J Cogn Neurosci. 2011 Dec;23(12):3703-12.

216. Putman P, Berling S. Cortisol acutely reduces selective attention for erotic words in healthy young men. Psychoneuroendocrinology. 2011 Oct;36(9):1407-17.

217. Wingenfeld K, et al. Working memory performance and cognitive flexibility after dexamethasone or hydrocortisone administration in healthy volunteers. Psychopharmacology (Berl). 2011 Oct;217(3):323-9

218. Römer S, et al. Oral cortisol impairs implicit sequence learning. Psychopharmacology (Berl). 2011 May;215(1):33-40

219. Kuehl LK, et al. Accelerated trace eyeblink conditioning after cortisol IV-infusion. Neurobiol Learn Mem. 2010 Nov;94(4):547-53

220. Richter S, et al. Cortisol rapidly disrupts prepulse inhibition in healthy men. Psychoneuroendocrinology. 2011 Jan;36(1):109-14

221. Tops M, et al. Acute cortisol effects on immediate free recall and recognition of nouns depend on stimulus valence. Psychophysiology. 2003 Mar;40(2):167-73

222. Hsu FC, et al. Effects of a single dose of cortisol on the neural correlates of episodic memory and error processing in healthy volunteers. Psychopharmacology (Berl). 2003 Jun;167(4):431-42

223. McAllister-Williams RH, Rugg MD. Effects of repeated cortisol administration on brain potential correlates of episodic memory retrieval. Psychopharmacology (Berl). 2002 Feb;160(1):74-83

224. Buchanan TW, et al. Exogenous cortisol exerts effects on the startle reflex independent of emotional modulation. Pharmacol Biochem Behav. 2001 Feb;68(2):203-10

225. Kirschbaum C, et al. Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sci. 1996;58(17):1475-83.

226. Young AH, et al. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl). 1999 Aug;145(3):260-6

227. Newcomer JW, et al. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch Gen Psychiatry. 1999 Jun;56(6):527-33µ

228. Schwegler K, et al. Cortisol reduces recall of explicit contextual pain memory in healthy young men. Psychoneuroendocrinology. 2010 Sep;35(8):1270-3.

229. Oei NY, et al. Hydrocortisone reduces emotional distracter interference in working memory. Psychoneuroendocrinology. 2009 Oct;34(9):1284-93.

230. Schwabe L, et al. Modulation of spatial and stimulus-response learning strategies by exogenous cortisol in healthy young women. Psychoneuroendocrinology. 2009 Apr;34(3):358-66

231. Rohleder N, et al. Effects of cortisol on emotional but not on neutral memory are correlated with peripheral glucocorticoid sensitivity of inflammatory cytokine production. Int J Psychophysiol. 2009 Apr;72(1):74-80.

232. Tollenaar MS, et al. Immediate and prolonged effects of cortisol, but not propranolol, on memory retrieval in healthy young men. Neurobiol Learn Mem. 2009 Jan;91(1):23-31

233. Sale MV, Ridding MC, Nordstrom MA. Cortisol inhibits neuroplasticity induction in human motor cortex. J Neurosci. 2008 Aug 13;28(33):8285-93.

234. Alhaj HA, Massey AE, McAllister-Williams RH. Effects of cortisol on the laterality of the neural correlates of episodic memory. J Psychiatr Res. 2008 Oct;42(12):971-81.

235. van Peer JM, Roelofs K, Spinhoven P. Cortisol administration enhances the coupling of midfrontal delta and beta oscillations. Int J Psychophysiol. 2008 Feb;67(2):144-50

236. Kuhlmann S, Wolf OT. A non-arousing test situation abolishes the impairing effects of cortisol on delayed memory retrieval in healthy women. Neurosci Lett. 2006 May 22;399(3):268-72

237. Kuhlmann S, Wolf OT. Arousal and cortisol interact in modulating memory consolidation in healthy young men. Behav Neurosci. 2006 Feb;120(1):217-23.

238. Abercrombie HC, Kalin NH, Davidson RJ. Acute cortisol elevations cause heightened arousal ratings of objectively nonarousing stimuli. Emotion. 2005 Sep;5(3):354-9.

239. Kuhlmann S, Wolf OT. Cortisol and memory retrieval in women: influence of menstrual cycle and oral contraceptives. Psychopharmacology (Berl). 2005 Nov;183(1):65-71.

240. Domes G, et al. Inverted-U function between salivary cortisol and retrieval of verbal memory after hydrocortisone treatment. Behav Neurosci. 2005 Apr;119(2):512-7

241. Buss C, Wolf OT, Witt J, Hellhammer DH. Autobiographic memory impairment following acute cortisol administration. Psychoneuroendocrinology. 2004 Sep;29(8):1093-6

242. Tops M, et al. Free recall of pleasant words from recency positions is especially sensitive to acute administration of cortisol. Psychoneuroendocrinology. 2004 Apr;29(3):327-38.

243. Porter RJ, et al. Effects of hydrocortisone administration on cognitive function in the elderly. J Psychopharmacol. 2002 Mar;16(1):65-71

244. Wolf OT, et al. Cortisol differentially affects memory in young and elderly men. Behav Neurosci. 2001 Oct;115(5):1002-11

245. Meir Drexler S, et al. Cortisol effects on fear memory reconsolidation in women. Psychopharmacology (Berl). 2016 Jul;233(14):2687-97.

246. Dierolf AM, et al. Effects of basal and acute cortisol on cognitive flexibility in an emotional task switching paradigm in men. Horm Behav. 2016 May;81:12-9.

247. Drexler SM, et al. Effects of cortisol on reconsolidation of reactivated fear memories. Neuropsychopharmacology. 2015 Dec;40(13):3036-43.

248. Cornelisse S, et al. Delayed effects of cortisol enhance fear memory of trace conditioning. Psychoneuroendocrinology. 2014 Feb;40:257-68

249. van Ast VA, et al. Time-dependent effects of cortisol on the contextualization of emotional memories. Biol Psychiatry. 2013 Dec 1;74(11):809-16.

250. Merz CJ, et al. Cortisol modifies extinction learning of recently acquired fear in men. Soc Cogn Affect Neurosci. 2014 Sep;9(9):1426-34

251. Henckens MJ, et al. Time-dependent effects of cortisol on selective attention and emotional interference: a functional MRI study. Front Integr Neurosci. 2012 Aug 28;6:66

252. Tollenaar MS, et al. Psychophysiological responding to emotional memories in healthy young men after cortisol and propranolol administration. Psychopharmacology (Berl). 2009 May;203(4):793-803

253. Putman P, Hermans EJ, van Honk J. Exogenous cortisol shifts a motivated bias from fear to anger in spatial working memory for facial expressions. Psychoneuroendocrinology. 2007 Jan;32(1):14-21.

254. Stark R, et al. Influence of the stress hormone cortisol on fear conditioning in humans: evidence for sex differences in the response of the prefrontal cortex. Neuroimage. 2006 Sep;32(3):1290-8.

255. Rimmele U, et al. Cortisol has different effects on human memory for emotional and neutral stimuli. Neuroreport. 2003 Dec 19;14(18):2485-8.

256. Abercrombie HC, et al. Cortisol variation in humans affects memory for emotionally laden and neutral information. Behav Neurosci. 2003 Jun;117(3):505-16

257. Buchanan TW, Lovallo WR. Enhanced memory for emotional material following stress-level cortisol treatment in humans. Psychoneuroendocrinology. 2001 Apr;26(3):307-17

258. Robertson CV, Immink MA, Marino FE. Exogenous cortisol administration: Effects on Risk Taking Behavior, Exercise Performance, and Physiological and Neurophysiological Responses. Front Physiol. 2016 Dec 27;7:640.

259. Ma ST, et al. Neural circuitry of emotion regulation: Effects of appraisal, attention, and cortisol administration. Cogn Affect Behav Neurosci. Paril 2017;17(2):437-451.

260. Kluen LM, Agorastos A, Wiedemann K, Schwabe L. Cortisol boosts risky decision-making behavior in men but not in women. Psychoneuroendocrinology. 2017 Oct;84:181-189.

261. Duesenberg M, et al. Does cortisol modulate emotion recognition and empathy? Psychoneuroendocrinology. 2016 Apr;66:221-7.

262. Gowin JL, et al. The role of cortisol and psychopathy in the cycle of violence. Psychopharmacology (Berl). 2013 Jun;227(4):661-72

263. Breitberg A, et al. Hydrocortisone infusion exerts dose- and sex-dependent effects on attention to emotional stimuli. Brain Cogn. 2013 Mar;81(2):247-55

264. van Ast VA, Vervliet B, Kindt M. Contextual control over expression of fear is affected by cortisol. Front Behav Neurosci. 2012 Oct 11;6:67

265. Merz CJ, et al. Oral contraceptive usage alters the effects of cortisol on implicit fear learning. Horm Behav. 2012 Sep;62(4):531-8

266. Henckens MJ, et al. Time-dependent effects of cortisol on selective attention and emotional interference: a functional MRI study. Front Integr Neurosci. 2012 Aug 28;6:66

267. Grillon C, et al. Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: a fear-potentiated startle study. Biol Psychiatry. 2011 Mar 15;69(6):549-55

268. Wirth MM, Scherer SM, Hoks RM, Abercrombie HC. The effect of cortisol on emotional responses depends on order of cortisol and placebo administration in a within-subject design. Psychoneuroendocrinology. 2011 Aug;36(7):945-54

269. Tabbert K, et al. Cortisol enhances neural differentiation during fear acquisition and extinction in contingency aware young women. Neurobiol Learn Mem. 2010 Oct;94(3):392-401.

270. Böhnke R, et al. Exogenous cortisol enhances aggressive behavior in females, but not in males. Psychoneuroendocrinology. 2010 Aug;35(7):1034-44.

271. Tops M, et al. State-dependent regulation of cortical activity by cortisol: an EEG study. Neurosci Lett. 2006 Aug 14;404(1-2):39-43

272. Merz C, et al. Investigating the impact of sex and cortisol on implicit fear conditioning with fMRI. Psychoneuroendocrinology. 2010 Jan;35(1):33-46

273. Kinner VL, Wolf OT, Merz CJ. Cortisol alters reward processing in the human brain. Horm Behav. 2016 Aug;84:75-83.

274. Montoya ER, et al. Cortisol administration induces global down-regulation of the brain’s reward circuitry. Psychoneuroendocrinology. 2014 Sep;47:31-42.

275. Singer N, et al. Acute psychosocial stress and everyday moral decision-making in young healthy men: The impact of cortisol. Horm Behav. 2017 Jul;93:72-81

276. Brown ES, et al. Hippocampal volume in healthy controls given 3-day stress doses of hydrocortisone. Neuropsychopharmacology. 2015 Mar 13;40(5):1216-21

277. Holz E, et al. Effects of acute cortisol administration on perceptual priming of trauma-related material. PLoS One. 2014 Sep 5;9(9):e104864

278. Bos PA, et al. Cortisol administration increases hippocampal activation to infant crying in males depending on childhood neglect. Hum Brain Mapp. 2014 Oct;35(10):5116-26

279. Schulz A, et al. Cortisol rapidly affects amplitudes of heartbeat-evoked brain potentials–implications for the contribution of stress to an altered perception of physical sensations? Psychoneuroendocrinology. 2013 Nov;38(11):2686-93

280. Demiralay C, et al. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone. World J Biol Psychiatry. 2012 Oct;13(7):526-34.

281. Bertsch K, et al. Exogenous cortisol facilitates responses to social threat under high provocation. Horm Behav. 2011 Apr;59(4):428-34.

282. Scheel M, Ströhle A, Bruhn H. Effects of short-term stress-like cortisol on cerebral metabolism: a proton magnetic resonance spectroscopy study at 3.0 T. J Psychiatr Res. 2010 Jun;44(8):521-6

283. Putman P, Hermans EJ, van Honk J. Cortisol administration acutely reduces threat-selective spatial attention in healthy young men. Physiol Behav. 2010 Mar 3;99(3):294-300

284. Vasa RA, et al. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology (Berl). 2009 Jun;204(3):445-55

285. Het S, Wolf OT. Mood changes in response to psychosocial stress in healthy young women: effects of pretreatment with cortisol. Behav Neurosci. 2007 Feb;121(1):11-20.

286. Reuter M. Impact of cortisol on emotions under stress and nonstress conditions: a pharmacopsychological approach. Neuropsychobiology.2002;46(1):41-

287. Wingenfeld K, et al. No effects of hydrocortisone and dexamethasone on pain sensitivity in healthy individuals. Eur J Pain. 2015 Jul;19(6):834-41

288. Michaux GP, et al. Experimental characterization of the effects of acute stresslike doses of hydrocortisone in human neurogenic hyperalgesia models. Pain. 2012 Feb;153(2):420-8

289. Mager DE, et al. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003 Nov;43(11):1216-27

290. Weckesser LJ, et al. Hydrocortisone Counteracts adverse stress effects on dual-task performance by improving visual sensory processes. J Cogn Neurosci. 2016 Nov;28(11):1784-1803

291. Ferreira de Sá DS, et al. Cortisol, but not intranasal insulin, affects the central processing of visual food cues. Psychoneuroendocrinology. 2014 Dec;50:311-20.

292. Schilling TM, et al. Rapid cortisol enhancement of psychomotor and startle reactions to side-congruent stimuli in a focused cross-modal choice reaction time paradigm. Eur Neuropsychopharmacol. 2014 Nov;24(11):1828-35

293. Ashton CH, et al. Subchronic hydrocortisone treatment alters auditory evoked potentials in normal subjects. Psychopharmacology (Berl). 2000 Sep;152(1):87-92

294. Beckwith BE, et al. Hydrocortisone reduces auditory sensitivity at high tonal frequencies in adult males. Pharmacol Biochem Behav. 1983 Sep;19(3):431-3

295. Born J, et al. Influences of cortisol on auditory evoked potentials (AEPs) and mood in humans. Neuropsychobiology. 1989;20(3):145-51.

296. Fehm-Wolfsdorf G, et al. Taste thresholds in man are differentially influenced by hydrocortisone and dexamethasone. Psychoneuroendocrinology. 1989;14(6):433-40.

297. Schilling TM, et al. Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation. Hum Brain Mapp. 2014 May;35(5):1944-56

298. Symonds CS, et al. Detection of the acute effects of hydrocortisone in the hippocampus using pharmacological fMRI. Eur Neuropsychopharmacol. 2012 Dec;22(12):867-74

299. Strelzyk F, et al. Tune it down to live it up? Rapid, nongenomic effects of cortisol on the human brain. J Neurosci. 2012 Jan 11;32(2):616-25

300. Lovallo WR, et al. Acute effects of hydrocortisone on the human brain: an fMRI study. Psychoneuroendocrinology. 2010 Jan;35(1):15-20.

301. McAllister-Williams RH, Massey AE, Fairchild G. Repeated cortisol administration attenuates the EEG response to buspirone in healthy volunteers: evidence for desensitization of the 5-HT1A autoreceptor. J Psychopharmacol. 2007 Nov;21(8):826-32.

302. Tessner KD, et al. The relation of cortisol levels with hippocampus volumes under baseline and challenge conditions. Brain Res. 2007 Nov 7;1179:70-8

303. Tops M, et al. Acute cortisol administration reduces subjective fatigue in healthy women. Psychophysiology. 2006 Nov;43(6):653-6.

304. Whitcomb JE, et al. Randomized trial of oral hydrocortisone and its effect on emergency physicians during night duty. WMJ. 2000 Oct;99(7):37-41, 46.

305. Plat L, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999 Sep;84(9):3082-92

306. Born J, et al. Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on sleep in normal man. J Clin Endocrinol Metab. 1989 May;68(5):904-11

307. Born J, et al. Differential effects of hydrocortisone, fluocortolone, and aldosterone on nocturnal sleep in humans. Acta Endocrinol (Copenh). 1987 Sep;116(1):129-37

308. Besedovsky L, et al. Cortisol increases CXCR4 expression but does not affect CD62L and CCR7 levels on specific T cell subsets in humans. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1322-9

309. Ekman B, et al. Altered chemokine Th1/Th2 balance in Addison’s disease: relationship with hydrocortisone dosing and quality of life. Horm Metab Res. 2014 Jan;46(1):48-53

310. Yeager MP, et al. Pretreatment with stress cortisol enhances the human systemic inflammatory response to bacterial endotoxin. Crit Care Med. 2009 Oct;37(10):2727-32.

311. Imrich R, et al. Pharmacological hyperprolactinemia attenuates hydrocortisone-induced expression of CD11b on human CD8+ cells in vivo. Neuroimmunomodulation. 2004;11(3):133-40.

312. Hennig J, Netter P, Voigt KH. Cortisol mediates redistribution of CD8+ but not of CD56+ cells after the psychological stress of public speaking. Psychoneuroendocrinology. 2001 Oct;26(7):673-87.

313. Goulding NJ, et al. Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone. Lancet. 1990 Jun 16;335(8703):1416-8

314. Tønnesen E, Christensen NJ, Brinkløv MM. Natural killer cell activity during cortisol and adrenaline infusion in healthy volunteers. Eur J Clin Invest. 1987 Dec;17(6):497-503

315. Djurhuus CB, et al. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab. 2004 Mar;286(3):E488-94

316. Djurhuus CB, et al. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E172-7

317. Vila G, et al. Acute effects of hydrocortisone on the metabolic response to a glucose load: increase in the first-phase insulin secretion. Eur J Endocrinol. 2010 Aug;163(2):225-31

318. Plat L, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996 Jan;270(1 Pt 1:E36-42.

319. Rassias AJ, Guyre PM, Yeager MP. Hydrocortisone at stress-associated concentrations helps maintain human heart rate variability during subsequent endotoxin challenge. J Crit Care. 2011 Dec;26(6):636.e1-5

320. Laviolle B, et al. Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers. Br J Clin Pharmacol. 2013 Feb;75(2):423-30

321. Heindl S, et al. Differential effects of hydrocortisone on sympathetic and hemodynamic responses to sympathoexcitatory manoeuvres in men. Steroids. 2006 Mar;71(3):206-13

322. Nonell A, et al. Chronic but not acute hydrocortisone treatment shifts the response to an orthostatic challenge towards parasympathetic activity. Neuroendocrinology. 2005;81(1):63-8.

323. Williamson PM, et al. Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):162-6.

324. Mangos GJ, et al. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens. 2000 Nov;13(11):1155-60.

325. Dodt C, et al. Acute suppression of muscle sympathetic nerve activity by hydrocortisone in humans. Hypertension. 2000 Mar;35(3):758-63

326. Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens. 2000 Mar;14(3):195-8

327. Macefield VG, et al. Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans. Blood Press. 1998 Jul;7(4):215-22

328. Pirpiris M, et al. Hydrocortisone-induced hypertension in men. The role of cardiac output. Am J Hypertens. 1993 Apr;6(4):287-94

329. Yurtsever T, et al. The acute and temporary modulation of PERIOD genes by hydrocortisone in healthy subjects. Chronobiol Int. 2016;33(9):1222-34

330. Johansen O, Brox J, Flaten MA. Placebo and Nocebo responses, cortisol, and circulating beta-endorphin. Psychosom Med. 2003 Sep-Oct;65(5):786-90

331. Novak E, et al. Anorectal pruritus after intravenous hydrocortisone sodium succinate and sodiumphosphate. Clin Pharmacol Ther. 1976 Jul;20(1):109-12

332. Hearn AJ, et al. Effect of sub-chronic hydrocortisone on responses to amphetamine in normal male volunteers. Psychopharmacology (Berl). 2004 Feb;171(4):458-64

333. Elfström J, Lindgren S. Metabolism of phenazone in man after hydrocortisone administration. Eur J Clin Pharmacol. 1978 Mar 17;13(1):69-72

334. Wachtel SR, Charnot A, de Wit H. Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans. Psychopharmacology (Berl). 2001 Jan;153(3):380-8

335. Gagliardi L, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014 Nov;99(11):4149-57.

336. Ekman B, et al. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf). 2012 Jul;77(1):18-25.

337. Riedel M, et al. Quality of life in patients with Addison’s disease: effects of different cortisol replacement modes. Exp Clin Endocrinol. 1993;101(2):106-11

338. Simunkova K, et al. Effect of a pre-exercise hydrocortisone dose on short-term physical performance in female patients with primary adrenal failure. Eur J Endocrinol. 2016 Jan;174(1):97-105.

339. Weise M, et al. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab. 2004 Aug;89(8):3679-84.

340. Laviolle B, et al. Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism. Clin Pharmacol Ther. 2010 Aug;88(2):183-90

341. Andersen M, et al. The effect of short-term cortisol changes on growth hormone responses to the pyridostigmine-growth-hormone-releasing-hormone test in healthy adults and patients with suspected growth hormone deficiency. Clin Endocrinol (Oxf). 1998 Aug;49(2):241-9.

342. Segerlantz M, et al. Effects of morning cortisol replacement on glucose and lipid metabolism in GH-treated subjects. Eur J Endocrinol. 2004 Dec;151(6):701-7

343. Giustina A, et al. Effect of pyridostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly. Horm Metab Res. 1994 Jun;26(6):288-92.

344. Cleare AJ, O’Keane V, Miell JP. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. Psychoneuroendocrinology. 2004 Jul;29(6):724-32

345. Cleare AJ, et al. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab. 2001 Aug;86(8):3545-54.

346. Cleare AJ, O’Keane V, Miell J. Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion. Clin Endocrinol (Oxf). 2001 Jul;55(1):113-9.

347. Cleare AJ, et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet. 1999 Feb 6;353(9151):455-8

348. McKenzie R, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA. 1998 Sep 23-30;280(12):1061-6.

349. Blockmans D, et al. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med. 2003 Jun 15;114(9):736-41

350. Putman P, et al. A single administration of cortisol acutely reduces preconscious attention for fear in anxious young men. Psychoneuroendocrinology. 2007 Aug;32(7):793-802

351. van Peer JM, Spinhoven P, Roelofs K. Psychophysiological evidence for cortisol-induced reduction in early bias for implicit social threat in social phobia. Psychoneuroendocrinology. 2010 Jan;35(1):21-32

352. van Peer JM, et al. Cortisol-induced enhancement of emotional face processing in social phobia depends on symptom severity and motivational context. Biol Psychol. 2009 May;81(2):123-30.

353. DeBattista C, et al. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2000 Aug;157(8):1334-7.

354. O’Dwyer AM, et al. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 1995 Feb 21;33(2):123-8

355. Schmid DA, et al. Acute cortisol administration increases sleep depth and growth hormone release in patients with major depression. J Psychiatr Res. 2008 Oct;42(12):991-9.

356. Bhagwagar Z, et al. Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. Biol Psychiatry. 2003 Nov 1;54(9):890-5

357. Kuehl LK, et al. Effects of cortisol on the memory bias for emotional words? A study in patients with depression and healthy participants using the Directed Forgetting task. J Psychiatr Res. 2017 Sep;92:191-198

358. Terfehr K, et al. Effects of acute hydrocortisone administration on declarative memory in patients with major depressive disorder: a placebo-controlled, double-blind crossover study. J Clin Psychiatry. 2011 Dec;72(12):1644-50

359. Terfehr K, et al. Hydrocortisone impairs working memory in healthy humans, but not in patients with major depressive disorder. Psychopharmacology (Berl). 2011 May;215(1):71-79

360. Schlosser N, et al. Effects of acute cortisol administration on autobiographical memory in patients with major depression and healthy controls. Psychoneuroendocrinology. 2010 Feb;35(2):316-20

361. Posener JA, et al. Cortisol feedbackduring the HPA quiescent period in patients with major depression. Am J Psychiatry. 2001 Dec;158(12):2083-5

362. Bhagwagar Z, Hafizi S, Cowen PJ. Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients. J Affect Disord. 2002 Dec;72(3):249-55

363. Schlosser N, et al. Effects of acute cortisol administration on response inhibition in patients with major depression and healthy controls. Psychiatry Res. 2013 Oct 30;209(3):439-46

364. Zohar J, et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies. Eur Neuropsychopharmacol. 2011 Nov;21(11):796-809.

365. Schelling G, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry. 2001 Dec15;50(12):978-85

366. Yehuda R, et al. Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: Randomized trial showing improved treatment retention and outcome. Psychoneuroendocrinology. 2015 Jan;51:589-97

367. Wingenfeld K, et al. Cortisol effects on autobiographic memory retrieval in PTSD: an analysis of word valence and time until retrieval. Stress. 2013 Sep;16(5):581-6.

368. Delahanty DL, et al. The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial. CNS Spectr. 2013 Apr;18(2):103-11

369. van Marle HJ, et al. The effect of exogenous cortisol during sleep on the behavioral and neural correlates of emotional memory consolidation in humans. Psychoneuroendocrinology. 2013 Sep;38(9):1639-49.

370. Wingenfeld K, et al. Cortisol has enhancing, rather than impairing effects on memory retrieval in PTSD. Psychoneuroendocrinology. 2012 Jul;37(7):1048-56.

371. Miller MW, et al. Hydrocortisone suppression of the fear-potentiated startle response and posttraumatic stress disorder. Psychoneuroendocrinology. 2011 Aug;36(7):970-80

372. Yehuda R, et al. Changes in relative glucose metabolic rate following cortisol administration in aging veterans with posttraumatic stress disorder: an FDG-PET neuroimaging study. J Neuropsychiatry Clin Neurosci. 2009 Spring;21(2):132-43.

373. Yehuda R, et al. Enhanced effects of cortisol administration on episodic and working memory in aging veterans with PTSD. Neuropsychopharmacology. 2007 Dec;32(12):2581-91.

374. Aerni A, et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry. 2004 Aug;161(8):1488-90

375. Ludäscher P, et al. No evidence for differential dose effects of hydrocortisone on intrusive memories in female patients with complex post-traumatic stress disorder–a randomized, double-blind, placebo-controlled, crossover study. J Psychopharmacol. 2015 Oct;29(10):1077-84

376. Brown ES, et al. A randomized, placebo-controlled proof-of-concept, crossover trial of phenytoin for hydrocortisone-induced declarative memory changes. J Affect Disord. 2013 Sep 5;150(2):551-8

377. Grossman R, et al. Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21.

378. Vythilingam M, Lawley M, Collin C, Bonne O, Agarwal R, Hadd K, Charney DS, Grillon C. Hydrocortisone impairs hippocampal-dependent trace eyeblink conditioning in post-traumatic stress disorder. Neuropsychopharmacology. 2006 Jan;31(1):182-8

379. Yehuda R, et al. Hydrocortisone responsiveness in Gulf War veterans with PTSD: effects on ACTH, declarative memory hippocampal [(18)F]FDG uptake on PET. Psychiatry Res. 2010 Nov 30;184(2):117-27

380. Yehuda R, et al. Alterations in cortisol negative feedback inhibition as examined using the ACTH response to cortisol administration in PTSD. Psychoneuroendocrinology. 2006 May;31(4):447-51

381. Nenke MA, et al. Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-controlled trial. Psychoneuroendocrinology. 2015 Jun;56:157-67

382. Yadav M, Durga P, Gopinath R. Role of hydrocortisone in prevention of pain on propofol injection. J Anaesthesiol Clin Pharmacol. 2011 Oct;27(4):470-4

383. Hornyak M, et al. Low-dose hydrocortisone in the evening modulates symptom severity in restless legs syndrome. Neurology. 2008 Apr 29;70(18):1620-2

384. Roquilly A, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA. 2011 Mar 23;305(12):1201-9

385. Wingenfeld K, et al. Effects of cortisol on memory in women with borderline personality disorder: role of co-morbid post-traumatic stress disorder and major depression. Psychol Med. 2013 Mar;43(3):495-505

386. Asehnoune K, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir Med. 2014 Sep;2(9):706-16

387. de Leon MJ, et al. Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer’s disease. J Clin Endocrinol Metab. 1997 Oct;82(10):3251-9

388. Tsai MS, et al. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med. 2007 Mar;25(3):318-25

389. Alam MR, Rahman MA, Ershad R. Role of very short-term intravenous hydrocortisone in reducing postdural puncture headache. J Anaesthesiol Clin Pharmacol. 2012 Apr;28(2):190-3

390. Salas G, Travaglianti M, Leone A, Couceiro C, Rodríguez S, Fariña D. Hydrocortisone for the treatment of refractory hypotension: a randomized controlled trial. An Pediatr (Barc). 2014 Jun;80(6):387-93.

391. Hochwald O, Palegra G, Osiovich H. Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian J Pediatr. 2014 Aug;81(8):808-10

392. Bassan MM, Sheikh-Hamad D. Prevention of lidocaine-infusion phlebitis b yheparin and hydrocortisone. Chest. 1983 Oct;84(4):439-4

393. Rubin LH, et al. Brief Report: Low-Dose Hydrocortisone Has Acute Enhancing Effects on Verbal Learning in HIV-Infected Men. J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):e65-e70

394. Bollaert PE, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998 Apr;26(4):645-50

395. Annane D, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862-71

396. Laviolle B, et al. Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock. Intensive Care Med. 2012 Aug;38(8):1306-14

397. Moreno R, et al. Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study. Intensive Care Med. 2011 Nov;37(11):1765-72

398. Aboab J, et al. Hydrocortisone effects on cardiovascular variability in septic shock: a spectral analysis approach. Crit Care Med. 2008 May;36(5):1481-6

399. Kaufmann I, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med. 2008 Feb;34(2):344-9

400. Oppert M, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005 Nov;33(11):2457-64

401. Keh D, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003 Feb 15;167(4):512-20

402. Wang C, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials. Anesth Analg. 2014 Feb;118(2):346-57

403. Chaudhury P, Marshall JC, Solomkin JS; Members of the Evidence Based Reviews in Surgery Group. CAGS and ACS evidence based reviews in surgery. 35: Efficacy and safety of low-dose hydrocortisone therapy in the treatment of septic shock. Can J Surg. 2010 Dec;53(6):415-7

404. Arabi YM, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ. 2010 Dec 14;182(18):1971-7

405. Sprung CL, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008 Jan 10;358(2):111-24

406. Mussack T, et al. Hemofiltration does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo. Eur J Med Res. 2005 Feb 28;10(2):81-7

407. Mussack T, et al. Hemofiltrastion does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo. Eur J Med Res. 2005 Jan 28;10(1):11-7.

408. Lv QQ, et al. Early initiation of low-dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial. Am J Emerg Med. 2017 Jun 5. [Epub ahead of print]

409. Keh D, et al; SepNet–Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: The HYPRESS Randomized Clinical Trial. JAMA. 2016 Nov 1;316(17):1775-1785

410. Plassais J, et al. Transcriptome modulation by hydrocortisone in severe burn shock: ancillary analysis of a prospective randomized trial. Crit Care. 2017 Jun 16;21(1):158

411. Venet F, et al. Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial. Crit Care. 2015 Jan 26;19:21

412. Mussack T, et al. Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock. Clin Chem Lab Med. 2005;43(3):259-68

413. Laaninen M, et al. Perioperative hydrocortisone reduces major complications after pancreaticoduodenectomy: a randomized controlled trial. Ann Surg. 2016 Nov;264(5):696-702.

414. Safavi M, et al. The evaluation of effects two different doses of hydrocortisone on the intensity of perioperative shivering in elective surgery under spinal anesthesia: A double-blind randomized controlled trial study. J Res Med Sci. 2016 Jun 14;21:40.

415. Laaninen M, et al. Perioperative hydrocortisone reduces major complications after pancreaticoduodenectomy: a randomized controlled trial. Ann Surg. 2016 Nov;264(5):696-702.

416. Kilger E, et al. Stress doses of hydrocortisone reduce systemic inflammatory response in patients undergoing cardiac surgery without cardiopulmonary bypass. Minerva Anestesiol. 2011Mar;77(3):268-74.

417. Weis F, et al. Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin-6 to interleukin-10 ratio and early outcome. Crit Care Med. 2009 May;37(5):1685-90.

418. Weis F, et al. Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study. J Thorac Cardiovasc Surg. 2006 Feb;131(2):277-82

419. Eydi M, Kolahdouzan K, Golzari SE. Effect of Intravenous Hydrocortisone on Preventing Postoperative Sore Throat Followed by Laryngeal Mask Airway Use in patients Undergoing Urogenital Surgeries. J Cardiovasc Thorac Res. 2013;5(1):29-33

420. Katayama Y, et al. A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007 Aug;38(8):2373-5.

421. Hashi K, et al. Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage–results of a multi-center controlled double-blind clinical study. No To Shinkei. 1988 Apr;40(4):373-82

422. Farrell RJ, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003 Apr;124(4):917-24

423. Rakela J, et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci. 1991 Sep;36(9):1223-8

424. Manolakopoulos S, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc. 2002 Apr;55(4):470-5

425. Tongyoo S, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016 Oct 15;20(1):329

426. Ho LI, et al. Postextubation laryngeal edema in adults. Risk factor evaluation and prevention by hydrocortisone. Intensive Care Med. 1996 Sep;22(9):933-6

427. Ussher M, et al. A randomised placebo-controlled trial of oral hydrocortisone for treating tobacco withdrawal symptoms. Psychopharmacology (Berl). 2011 Jul;216(1):43-51

428. Walter M, et al. Effects of cortisol administration on craving in heroin addicts. Transl Psychiatry. 2015 Jul 28;5:e610

429. Hopper JW, et al. Effects of acute cortisol and cocaine administration on attention, recall and recognition task performance in individuals with cocaine dependence. Hum Psychopharmacol. 2004 Oct;19(7):511-6

430. Domes G, et al. Inverted-U function between salivary cortisol and retrieval of verbal memory after hydrocortisone treatment. Behav Neurosci. 2005 Apr;119(2):512-7

431. de Silva HA, et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011 May;8(5):e1000435

432. Gawarammana IB, et al. Parallel infusion of hydrocortisone +/- chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med J Aust. 2004 Jan 5;180(1):20-3

433. Abroug F, et al. High-dose hydrocortisone hemisuccinate in scorpion envenomation. Ann Emerg Med. 1997 Jul;30(1):23-7.

434. Meghrajani CF, et al. A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis. Expert Rev Clin Pharmacol. 2016;9(3):483-91.

435. Al-Ghnaniem R, et al. 1% hydrocortisone ointment is an effective treatment of pruritus ani: a pilot randomized controlled crossover trial. Int J Colorectal Dis. 2007 Dec;22(12):1463-7

436. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997 Jul-Aug;19(4):710-9

437. Roth HL, Brown EP. Hydrocortisone valerate. Double-blind comparison with two other topical steroids. Cutis. 1978 May;21(5):695-8.

438. Yasuda T. Clinical experiences with hydrocortisone 17-butyrate. Dermatologica. 1976;152 Suppl 1:221-9.

439. Zhai H, et al. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol Appl Skin Physiol. 2000 Nov-Dec;13(6):352-7.

440. Manfre M, et al. Hydrocortisone Cream to Reduce Perineal Pain after Vaginal Birth: A Randomized Controlled Trial. MCN Am J Matern Child Nurs. 2015 Sep-Oct;40(5):306-12.

441. Greer IA, Cameron AD. Topical pramoxine and hydrocortisone foam versus placebo in relief of post partum episiotomy symptoms and wound healing. Scott Med J. 1984 Apr;29(2):104-6

442. Rother M, Rother I. Placebo controlled, crossover validation study of oral ibuprofen and topical hydrocortisone- 21-acetate for a model of ultraviolet B radiation (UVR)-induced pain and inflammation. J Pain Res. 2011;4:357-63

443. González Ochoa A, Vargas Ocampo F. Treatment of pityriasis alba with a combination of coal tar, diiodohydroxyquinolin and hydrocortisone. Med Cutan Ibero Lat Am. 1980;8(1-3):69-72

444. Maibach HI. Iodochlorhydroxyquin-hydrocortisone treatment of fungal infections. Double-blind trial. Arch Dermatol. 1978 Dec;114(12):1773-5.

445. Hull CM, Brunton S. The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis. Postgrad Med. 2010 Sep;122(5):1-6.

446. Evans TG, et al. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother. 2002 Jun;46(6):1870-4

447. Serup J, Holm P. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. Dermatologica. 1985;170(4):189-94

448. Vierhapper H, Nowotny P, Waldhäusl W. Sex-specific differences in cortisol production rates in humans. Metabolism. 1998 Aug;47(8):974-6.

449. https://en.wikipedia.org/wiki/Body_surface_area

450. Kraan GP, et al. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab. 1998 Apr;83(4):1247-52.

451. Esteban NV, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991 Jan;72(1):39-45.

452. Villanueva AL, et al. Increased cortisol production in women runners. J Clin Endocrinol Metab. 1986 Jul;63(1):133-6.

453. Sandle GI, Keir MJ, Record CO. Inter-relationships between the absorptions of hydrocortisone, sodium, water and actively transported organic solutes in the human jejunum. Eur J Clin Pharmacol. 1982;23(2):177-82.

454. Mah PM, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004 Sep;61(3):367-75

455. Czock D, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98 (“the clinical efficacy of low-dose glucocorticoid regimens might be increased with twice-daily glucocorticoid administration”)

456. Murray RD, et al; the EU-AIR Investigators. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity – data from the EU-AIR. Clin Endocrinol (Oxf). 2017 Mar;86(3):340-346.

457. Maguire AM, et al. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. Pediatrics. 2007 Jul;120(1):e164-71.

458. Bliesener N, et al. Dose distribution in hydrocortisone replacement therapy has a significant influence on urine free cortisol excretion. Exp Clin Endocrinol Diabetes. 2003 Oct;111(7):443-6

459. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990 Aug;19(2):126-46 (“an alternate-day regimen with prednisone yields fewer biological effects”)

460. Czock D, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98

461. Jefferies WM. Cortisol and immunity. Med Hypotheses. 1991 Mar;34(3):198-208.